Peptide Comparison
KPV (Alpha-MSH Fragment)vsThymosin Beta-4
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
At a Glance
Quick
comparison
Dose Range
KPV (Alpha-MSH Fragment)
200 mcg–1500 mcg mcg
Thymosin Beta-4
2–5 mg
Frequency
KPV (Alpha-MSH Fragment)
Once daily
Thymosin Beta-4
Twice weekly
Administration
KPV (Alpha-MSH Fragment)
Oral
Thymosin Beta-4
Subcutaneous injection
Cycle Length
KPV (Alpha-MSH Fragment)
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset Speed
KPV (Alpha-MSH Fragment)
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence Level
KPV (Alpha-MSH Fragment)
Strong human trials (Phase 3 or FDA approved)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Anti-Inflammatory
Gut Health
Healing & Recovery
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical Data
Compound
specifications
KPV (Alpha-MSH Fragment)
Molecular Formula
C16H30N4O4
Molecular Weight
342.43 Da
Half-Life
Short peptide half-life; improved by nanoparticle and hydrogel formulations
Bioavailability
Oral uptake via PepT1 transporter; enhanced by nanoparticle formulations
CAS Number
67727-97-3
Thymosin Beta-4
Molecular Formula
C212H350N56O78S
Molecular Weight
4963
Half-Life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS Number
77591-33-4
Applications
Best
suited for
KPV (Alpha-MSH Fragment)
Inflammatory bowel disease research
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gut anti-inflammatory therapy development
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Skin inflammation and wound healing
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated inflammation studies
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety Profile
Side
effects
KPV (Alpha-MSH Fragment)
Common
- Injection Site Reaction
- Mild GI Effects
- Transient Skin Effects
- Mild Immune Modulation
- Peptide Stability Concerns
Uncommon
- Theoretical Immunosuppression
Serious
- Immune Tolerance Development
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research Status
Safety
& evidence
KPV (Alpha-MSH Fragment)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
Contraindications
- xNot approved for human clinical use
- xUnknown interactions with immunosuppressive medications
- xInsufficient safety data for pregnancy and lactation
- xPotential melanocortin receptor effects in susceptible individuals
Thymosin Beta-4
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- xActive systemic infections
- xSevere immunosuppression
- xHypersensitivity to thymosin or any component
- xPregnancy (insufficient safety data)
Decision Guide
Which is
right for you?
Choose KPV (Alpha-MSH Fragment) if...
- Inflammatory bowel disease research
- Gut anti-inflammatory therapy development
- Skin inflammation and wound healing
- Cytokine-mediated inflammation studies
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation